Share Price and Basic Stock Data
Last Updated: October 27, 2025, 10:11 am
| PEG Ratio | 1.36 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Genesys International Corporation Ltd operates in the IT Consulting and Software sector, focusing on providing technological solutions to clients. The company reported a stock price of ₹559 and a market capitalization of ₹2,332 Cr. Over the past financial years, Genesys has demonstrated a robust growth trajectory in its sales figures. For instance, sales rose from ₹120 Cr in FY 2022 to ₹181 Cr in FY 2023, and further to ₹198 Cr in FY 2024. The trailing twelve months (TTM) sales stood at ₹326 Cr, indicating a significant increase. This growth momentum is evident in quarterly results, where revenue peaked at ₹94.16 Cr in Q4 FY 2025. The company has effectively capitalized on market opportunities, reflected in the rising sales figures, although the quarterly sales have seen fluctuations, particularly in Q1 FY 2024, which recorded a drop to ₹34.55 Cr. Overall, Genesys’s revenue trends highlight its capacity to adapt and thrive in a competitive environment.
Profitability and Efficiency Metrics
Genesys International has showcased varying profitability metrics, with a reported net profit of ₹56 Cr and a net profit margin of 18.03% for FY 2025. The operating profit margin (OPM) stood at 41.63%, which is favorable compared to typical sector margins. However, the company experienced a challenging period in Q1 FY 2024, where it reported a net loss of ₹5.46 Cr. Despite these ups and downs, the return on equity (ROE) was recorded at 10.8%, while the return on capital employed (ROCE) stood at 15.0%, indicating efficient utilization of capital. The interest coverage ratio (ICR) was impressive at 16.68x, showcasing the company’s ability to meet interest obligations comfortably. This robust financial performance is complemented by operational efficiency, as evidenced by the cash conversion cycle (CCC) of 261 days, which remains a focus area for further enhancement.
Balance Sheet Strength and Financial Ratios
The financial health of Genesys International is reflected in its balance sheet, with total assets amounting to ₹778 Cr and total liabilities at ₹778 Cr as of FY 2025. The company reported reserves of ₹536 Cr, with borrowings at ₹122 Cr, indicating a manageable debt level. The current ratio stood at 2.41x, suggesting strong liquidity and the ability to cover short-term obligations. The price-to-book value (P/BV) ratio was noted at 5.15x, which is relatively high, indicating that the stock may be overvalued compared to its book value. The company has maintained a low long-term debt-to-equity ratio of 0.02, reflecting a conservative approach to leveraging. However, the total debt-to-equity ratio of 0.19 suggests some reliance on debt for growth, which could pose risks if not managed prudently. Overall, Genesys’s balance sheet reveals a solid foundation, though continued vigilance on debt management is essential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genesys International indicates a diverse ownership structure, with promoters holding 31.55%, foreign institutional investors (FIIs) at 4.69%, domestic institutional investors (DIIs) at 1.47%, and the public holding 62.27%. The number of shareholders has seen a significant increase, rising from 7,401 in December 2022 to 45,192 by September 2025. This growth signifies increasing investor interest and confidence in the company. However, the declining promoter stake, from 40.60% in December 2022 to the current 31.55%, may raise concerns about insider confidence. The modest presence of institutional investors could suggest a need for better engagement with FIIs and DIIs to enhance market credibility. Overall, the shareholding pattern reflects a generally positive sentiment towards Genesys, yet the declining promoter share could be a focal point for future monitoring.
Outlook, Risks, and Final Insight
Looking ahead, Genesys International is positioned to leverage its growth trajectory in the IT consulting space, especially with the reported increase in revenues and profitability metrics. However, the company faces inherent risks, including fluctuating sales, as evidenced by the decline in Q1 FY 2024 and the potential impact of economic conditions on client spending. The company’s high P/BV ratio could indicate overvaluation, which may affect investor sentiment adversely. Additionally, the declining promoter stake could trigger concerns regarding long-term commitment to the company’s vision. If Genesys can maintain its operational efficiency, improve its sales consistency, and enhance investor relations, it may solidify its market position. Conversely, failure to address these risks could hinder its growth potential. As such, while opportunities abound, diligent management of these challenges will be critical for sustained success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genesys International Corporation Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Visesh Infotecnics Ltd | 125 Cr. | 0.33 | 0.38/0.33 | 1.12 | 0.00 % | 2.21 % | 2.23 % | 1.00 | |
| Mudunuru Ltd | 31.4 Cr. | 9.94 | 10.2/4.43 | 0.25 | 0.00 % | 27.0 % | 90.7 % | 2.00 | |
| Naapbooks Ltd | 155 Cr. | 144 | 194/99.8 | 34.7 | 33.2 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 34.6 Cr. | 270 | 310/140 | 26.8 | 19.0 | 0.37 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 5.86 Cr. | 1.21 | 1.73/0.91 | 53.2 | 2.52 | 0.00 % | 2.14 % | 2.15 % | 2.00 |
| Industry Average | 19,338.99 Cr | 564.29 | 143.94 | 119.00 | 0.53% | 14.92% | 20.95% | 6.84 |
All Competitor Stocks of Genesys International Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.69 | 37.38 | 54.43 | 46.62 | 34.55 | 33.19 | 59.34 | 71.17 | 55.76 | 72.02 | 89.09 | 94.16 | 70.87 |
| Expenses | 30.95 | 26.42 | 35.07 | 30.30 | 28.75 | 25.49 | 28.56 | 34.92 | 35.35 | 42.64 | 46.52 | 44.39 | 41.37 |
| Operating Profit | 11.74 | 10.96 | 19.36 | 16.32 | 5.80 | 7.70 | 30.78 | 36.25 | 20.41 | 29.38 | 42.57 | 49.77 | 29.50 |
| OPM % | 27.50% | 29.32% | 35.57% | 35.01% | 16.79% | 23.20% | 51.87% | 50.93% | 36.60% | 40.79% | 47.78% | 52.86% | 41.63% |
| Other Income | 1.37 | 1.93 | 1.79 | 1.41 | 0.93 | 1.11 | 2.53 | 0.46 | 1.41 | 1.00 | 1.84 | 0.11 | 1.27 |
| Interest | 0.54 | 0.56 | 0.35 | 1.22 | 0.67 | 0.72 | 1.09 | 1.43 | 1.24 | 1.88 | 2.58 | 3.08 | 3.18 |
| Depreciation | 8.14 | 8.90 | 9.30 | 10.86 | 11.30 | 10.94 | 11.06 | 11.18 | 11.80 | 12.25 | 15.69 | 15.29 | 15.43 |
| Profit before tax | 4.43 | 3.43 | 11.50 | 5.65 | -5.24 | -2.85 | 21.16 | 24.10 | 8.78 | 16.25 | 26.14 | 31.51 | 12.16 |
| Tax % | 55.53% | 5.83% | 32.70% | 64.42% | 4.39% | 20.70% | 25.71% | 38.63% | 39.64% | 31.69% | 20.73% | 39.73% | 42.60% |
| Net Profit | 1.97 | 3.23 | 7.73 | 2.00 | -5.46 | -3.43 | 15.73 | 14.79 | 5.30 | 11.09 | 20.71 | 19.00 | 6.98 |
| EPS in Rs | 1.36 | 1.30 | 2.13 | 0.57 | -1.41 | -0.87 | 4.19 | 3.76 | 1.36 | 2.83 | 5.20 | 4.76 | 1.71 |
Last Updated: August 20, 2025, 10:30 am
Below is a detailed analysis of the quarterly data for Genesys International Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 70.87 Cr.. The value appears to be declining and may need further review. It has decreased from 94.16 Cr. (Mar 2025) to 70.87 Cr., marking a decrease of 23.29 Cr..
- For Expenses, as of Jun 2025, the value is 41.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 44.39 Cr. (Mar 2025) to 41.37 Cr., marking a decrease of 3.02 Cr..
- For Operating Profit, as of Jun 2025, the value is 29.50 Cr.. The value appears to be declining and may need further review. It has decreased from 49.77 Cr. (Mar 2025) to 29.50 Cr., marking a decrease of 20.27 Cr..
- For OPM %, as of Jun 2025, the value is 41.63%. The value appears to be declining and may need further review. It has decreased from 52.86% (Mar 2025) to 41.63%, marking a decrease of 11.23%.
- For Other Income, as of Jun 2025, the value is 1.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Mar 2025) to 1.27 Cr., marking an increase of 1.16 Cr..
- For Interest, as of Jun 2025, the value is 3.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.08 Cr. (Mar 2025) to 3.18 Cr., marking an increase of 0.10 Cr..
- For Depreciation, as of Jun 2025, the value is 15.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.29 Cr. (Mar 2025) to 15.43 Cr., marking an increase of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.16 Cr.. The value appears to be declining and may need further review. It has decreased from 31.51 Cr. (Mar 2025) to 12.16 Cr., marking a decrease of 19.35 Cr..
- For Tax %, as of Jun 2025, the value is 42.60%. The value appears to be increasing, which may not be favorable. It has increased from 39.73% (Mar 2025) to 42.60%, marking an increase of 2.87%.
- For Net Profit, as of Jun 2025, the value is 6.98 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 6.98 Cr., marking a decrease of 12.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.71. The value appears to be declining and may need further review. It has decreased from 4.76 (Mar 2025) to 1.71, marking a decrease of 3.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:19 am
| Metric | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 60 | 47 | 64 | 114 | 115 | 112 | 80 | 120 | 181 | 198 | 311 | 326 |
| Expenses | 42 | 47 | 40 | 48 | 78 | 96 | 98 | 81 | 92 | 122 | 117 | 168 | 175 |
| Operating Profit | 53 | 13 | 7 | 16 | 36 | 19 | 13 | -2 | 28 | 59 | 81 | 143 | 151 |
| OPM % | 56% | 21% | 16% | 25% | 32% | 17% | 12% | -2% | 23% | 32% | 41% | 46% | 46% |
| Other Income | -1 | 2 | 6 | 3 | 4 | 3 | 4 | -30 | -42 | 6 | 5 | 4 | 4 |
| Interest | 0 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 5 | 10 | 11 |
| Depreciation | 7 | 8 | 7 | 13 | 14 | 19 | 21 | 19 | 19 | 37 | 44 | 55 | 59 |
| Profit before tax | 45 | 5 | 5 | 5 | 24 | 0 | -7 | -54 | -36 | 25 | 37 | 83 | 86 |
| Tax % | -1% | 11% | 6% | -41% | 28% | 1,108% | -23% | -5% | 11% | 40% | 42% | 32% | |
| Net Profit | 46 | 4 | 2 | 6 | 17 | -4 | -5 | -52 | -40 | 15 | 22 | 56 | 58 |
| EPS in Rs | 15.42 | 1.43 | 0.73 | 2.11 | 5.50 | 1.73 | 0.61 | -13.75 | 4.28 | 5.05 | 5.58 | 14.12 | 14.50 |
| Dividend Payout % | 8% | 9% | 17% | 6% | 2% | 7% | -0% | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 183.33% | -123.53% | -25.00% | -940.00% | 23.08% | 137.50% | 46.67% | 154.55% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | -16.67% | -306.86% | 98.53% | -915.00% | 963.08% | 114.42% | -90.83% | 107.88% |
Genesys International Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 38% |
| TTM: | 49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 98% |
| 3 Years: | -3% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 63% |
| 3 Years: | 1% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 4:40 am
Balance Sheet
Last Updated: October 10, 2025, 2:04 pm
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 19 | 20 | 20 |
| Reserves | 126 | 193 | 195 | 152 | 209 | 208 | 197 | 158 | 189 | 387 | 469 | 536 |
| Borrowings | 2 | 12 | 14 | 22 | 24 | 26 | 16 | 14 | 26 | 39 | 60 | 122 |
| Other Liabilities | 23 | 25 | 37 | 135 | 136 | 134 | 136 | 117 | 88 | 61 | 86 | 100 |
| Total Liabilities | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 |
| Fixed Assets | 46 | 21 | 22 | 179 | 217 | 208 | 203 | 194 | 138 | 157 | 156 | 128 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 65 | 113 | 156 |
| Investments | 8 | 122 | 156 | 25 | 11 | 11 | 15 | 8 | 6 | 51 | 0 | 0 |
| Other Assets | 111 | 101 | 84 | 120 | 157 | 165 | 147 | 102 | 156 | 232 | 366 | 495 |
| Total Assets | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 |
Below is a detailed analysis of the balance sheet data for Genesys International Corporation Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
- For Reserves, as of Mar 2025, the value is 536.00 Cr.. The value appears strong and on an upward trend. It has increased from 469.00 Cr. (Mar 2024) to 536.00 Cr., marking an increase of 67.00 Cr..
- For Borrowings, as of Mar 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 60.00 Cr. (Mar 2024) to 122.00 Cr., marking an increase of 62.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 86.00 Cr. (Mar 2024) to 100.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 778.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 635.00 Cr. (Mar 2024) to 778.00 Cr., marking an increase of 143.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 128.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2024) to 128.00 Cr., marking a decrease of 28.00 Cr..
- For CWIP, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 43.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 495.00 Cr.. The value appears strong and on an upward trend. It has increased from 366.00 Cr. (Mar 2024) to 495.00 Cr., marking an increase of 129.00 Cr..
- For Total Assets, as of Mar 2025, the value is 778.00 Cr.. The value appears strong and on an upward trend. It has increased from 635.00 Cr. (Mar 2024) to 778.00 Cr., marking an increase of 143.00 Cr..
Notably, the Reserves (536.00 Cr.) exceed the Borrowings (122.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 51.00 | 1.00 | -7.00 | -6.00 | 12.00 | -7.00 | -3.00 | -16.00 | 2.00 | 20.00 | 21.00 | 21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Working Capital Days | 172 | 326 | 172 | 105 | 99 | 215 | 223 | 126 | 82 | 212 | 269 | 291 |
| ROCE % | 41% | 3% | 3% | 8% | 1% | -1% | -7% | 4% | 7% | 8% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 14.14 | 5.78 | 5.44 | 4.28 | -13.77 |
| Diluted EPS (Rs.) | 14.03 | 5.74 | 5.29 | 4.28 | -13.34 |
| Cash EPS (Rs.) | 27.92 | 16.72 | 13.81 | -6.55 | -10.57 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Revenue From Operations / Share (Rs.) | 78.14 | 50.14 | 47.97 | 38.14 | 25.48 |
| PBDIT / Share (Rs.) | 36.80 | 21.64 | 17.18 | 9.83 | -0.49 |
| PBIT / Share (Rs.) | 22.98 | 10.39 | 7.33 | 3.74 | -6.51 |
| PBT / Share (Rs.) | 20.77 | 9.40 | 6.62 | -11.44 | -17.43 |
| Net Profit / Share (Rs.) | 14.10 | 5.47 | 3.95 | -12.65 | -16.59 |
| NP After MI And SOA / Share (Rs.) | 14.13 | 5.58 | 5.05 | 4.28 | -13.75 |
| PBDIT Margin (%) | 47.09 | 43.16 | 35.81 | 25.78 | -1.95 |
| PBIT Margin (%) | 29.40 | 20.72 | 15.27 | 9.79 | -25.53 |
| PBT Margin (%) | 26.58 | 18.75 | 13.79 | -29.98 | -68.43 |
| Net Profit Margin (%) | 18.03 | 10.90 | 8.24 | -33.17 | -65.09 |
| NP After MI And SOA Margin (%) | 18.07 | 11.13 | 10.53 | 11.21 | -53.96 |
| Return on Networth / Equity (%) | 10.12 | 4.51 | 4.70 | 6.54 | -24.77 |
| Return on Capital Employeed (%) | 15.53 | 7.81 | 6.33 | 4.76 | -7.59 |
| Return On Assets (%) | 7.22 | 3.47 | 3.77 | 4.17 | -14.11 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.04 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.10 | 0.07 | 0.09 | 0.03 |
| Asset Turnover Ratio (%) | 0.44 | 0.34 | 0.43 | 0.41 | 0.23 |
| Current Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Quick Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Interest Coverage Ratio (X) | 16.68 | 21.89 | 24.33 | 12.45 | -0.53 |
| Interest Coverage Ratio (Post Tax) (X) | 7.39 | 6.53 | 6.60 | 3.19 | -6.06 |
| Enterprise Value (Cr.) | 2956.65 | 2312.97 | 1258.23 | 1817.61 | 404.10 |
| EV / Net Operating Revenue (X) | 9.51 | 11.67 | 6.95 | 15.19 | 5.08 |
| EV / EBITDA (X) | 20.18 | 27.03 | 19.40 | 58.93 | -260.36 |
| MarketCap / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| Price / BV (X) | 5.15 | 4.78 | 3.06 | 8.73 | 1.84 |
| Price / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.13 |
After reviewing the key financial ratios for Genesys International Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 14.14. This value is within the healthy range. It has increased from 5.78 (Mar 24) to 14.14, marking an increase of 8.36.
- For Diluted EPS (Rs.), as of Mar 25, the value is 14.03. This value is within the healthy range. It has increased from 5.74 (Mar 24) to 14.03, marking an increase of 8.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.92. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 27.92, marking an increase of 11.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 78.14. It has increased from 50.14 (Mar 24) to 78.14, marking an increase of 28.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.80. This value is within the healthy range. It has increased from 21.64 (Mar 24) to 36.80, marking an increase of 15.16.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.98. This value is within the healthy range. It has increased from 10.39 (Mar 24) to 22.98, marking an increase of 12.59.
- For PBT / Share (Rs.), as of Mar 25, the value is 20.77. This value is within the healthy range. It has increased from 9.40 (Mar 24) to 20.77, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 14.10. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 14.10, marking an increase of 8.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 14.13. This value is within the healthy range. It has increased from 5.58 (Mar 24) to 14.13, marking an increase of 8.55.
- For PBDIT Margin (%), as of Mar 25, the value is 47.09. This value is within the healthy range. It has increased from 43.16 (Mar 24) to 47.09, marking an increase of 3.93.
- For PBIT Margin (%), as of Mar 25, the value is 29.40. This value exceeds the healthy maximum of 20. It has increased from 20.72 (Mar 24) to 29.40, marking an increase of 8.68.
- For PBT Margin (%), as of Mar 25, the value is 26.58. This value is within the healthy range. It has increased from 18.75 (Mar 24) to 26.58, marking an increase of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 18.03. This value exceeds the healthy maximum of 10. It has increased from 10.90 (Mar 24) to 18.03, marking an increase of 7.13.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has increased from 11.13 (Mar 24) to 18.07, marking an increase of 6.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.12. This value is below the healthy minimum of 15. It has increased from 4.51 (Mar 24) to 10.12, marking an increase of 5.61.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.53. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 15.53, marking an increase of 7.72.
- For Return On Assets (%), as of Mar 25, the value is 7.22. This value is within the healthy range. It has increased from 3.47 (Mar 24) to 7.22, marking an increase of 3.75.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.19, marking an increase of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.34 (Mar 24) to 0.44, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Quick Ratio (X), as of Mar 25, the value is 2.41. This value exceeds the healthy maximum of 2. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 16.68. This value is within the healthy range. It has decreased from 21.89 (Mar 24) to 16.68, marking a decrease of 5.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.39. This value is within the healthy range. It has increased from 6.53 (Mar 24) to 7.39, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,956.65. It has increased from 2,312.97 (Mar 24) to 2,956.65, marking an increase of 643.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has decreased from 11.67 (Mar 24) to 9.51, marking a decrease of 2.16.
- For EV / EBITDA (X), as of Mar 25, the value is 20.18. This value exceeds the healthy maximum of 15. It has decreased from 27.03 (Mar 24) to 20.18, marking a decrease of 6.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For Price / BV (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 3. It has increased from 4.78 (Mar 24) to 5.15, marking an increase of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesys International Corporation Ltd:
- Net Profit Margin: 18.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.53% (Industry Average ROCE: 14.77%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.12% (Industry Average ROE: 19.93%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.39
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.5 (Industry average Stock P/E: 110.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | 73-A, SDF-III, SEEPZ, Mumbai Maharashtra 400096 | investors@igenesys.com http://www.igenesys.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sajid Malik | Chairman & Managing Director |
| Ms. Bharti Sinha | Independent Director |
| Mr. Manish Patel | Independent Director |
| Mr. Ganesh Acharya | Independent Director |
| Mr. Omprakash Hemrajani | Director |
| Dr. Yogita Shukla | Director |
FAQ
What is the intrinsic value of Genesys International Corporation Ltd?
Genesys International Corporation Ltd's intrinsic value (as of 27 October 2025) is 462.67 which is 11.20% lower the current market price of 521.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,174 Cr. market cap, FY2025-2026 high/low of 1,055/455, reserves of ₹536 Cr, and liabilities of 778 Cr.
What is the Market Cap of Genesys International Corporation Ltd?
The Market Cap of Genesys International Corporation Ltd is 2,174 Cr..
What is the current Stock Price of Genesys International Corporation Ltd as on 27 October 2025?
The current stock price of Genesys International Corporation Ltd as on 27 October 2025 is 521.
What is the High / Low of Genesys International Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesys International Corporation Ltd stocks is 1,055/455.
What is the Stock P/E of Genesys International Corporation Ltd?
The Stock P/E of Genesys International Corporation Ltd is 37.5.
What is the Book Value of Genesys International Corporation Ltd?
The Book Value of Genesys International Corporation Ltd is 140.
What is the Dividend Yield of Genesys International Corporation Ltd?
The Dividend Yield of Genesys International Corporation Ltd is 0.00 %.
What is the ROCE of Genesys International Corporation Ltd?
The ROCE of Genesys International Corporation Ltd is 15.0 %.
What is the ROE of Genesys International Corporation Ltd?
The ROE of Genesys International Corporation Ltd is 10.8 %.
What is the Face Value of Genesys International Corporation Ltd?
The Face Value of Genesys International Corporation Ltd is 5.00.
